复方丹参滴丸联合依帕司他治疗2型糖尿病周围神经病变114例临床效果与电生理变化研究
|
摘要
目的研究复方丹参滴丸联合依帕司他治疗2型糖尿病周围神经病变114例的临床效果与电生理变化。方法按照入院顺序将114例2型糖尿病周围神经病变患者分为观察组(57例)和对照组(57例)。所有患者采取依帕司他,观察组患者在此基础上联合服用复方丹参滴丸。比较两组患者治疗后的临床疗效,测定两组患者治疗前后的感觉阈值变化,以及肌电图运动神经和感觉神经传导速度比较。结果治疗后,观察组患者总的有效率(94.74%)显著高于对照组(85.97%),差异具有统计学意义(P<0.05);治疗后,观察组患者的感觉阈值(2.5±0.5)显著低于对照组(3.6±0.7),差异具有统计学意义(P<0.05);治疗后,观察组患者的肌电图运动神经和感觉神经传导速度显著快于对照组,差异具有统计学意义(P<0.05)。结论复方丹参滴丸联合依帕司他治疗2型糖尿病周围神经病变,可提高患者的神经传导速度,其临床疗效良好,值得广泛推广使用。
Objective To study the CSDP Joint epalrestat treatment of type 2 diabetes,peripheral neuropathy and electrophysiological effects of changes in 114 cases.Methods According to the order of the 114 cases hospitalized type 2 diabetic peripheral neuropathy were divided into observation groups(57 patients) and control group(57 cases).All patients taking epalrestat,observation groups were given joint administration CSDP on the basis of epalrestat.The clinical efficacy of the two groups of patients after treatment were compared,two groups of patients' perception threshold were measured before and after treatment,as well as EMG motor and sensory nerve conduction velocitywere compared.Results After treatment,the observation group total effective rate(94.74%) was significantly higher(85.97%) than the control group,which the difference was a statistically significant(F <0.05);after treatment,the perception threshold observation group of patients(2.5 ± 0.5) was significantly lower than the control group(3.6 ± 0.7),which the difference was a statistically significant(F <0.05);after treatment,observation group of patients with EMG motor and sensory nerve conduction velocity was significantly faster than the control group,which the difference was a statistically significance(F <0.05).Conclusions CSDP Joint epalrestat treatment of type 2 diabetic peripheral neuropathy,which can be increased in patients' nerve conduction velocity and get a good clinical efficacy,it is widely used.
Objective To study the CSDP Joint epalrestat treatment of type 2 diabetes,peripheral neuropathy and electrophysiological effects of changes in 114 cases.Methods According to the order of the 114 cases hospitalized type 2 diabetic peripheral neuropathy were divided into observation groups(57 patients) and control group(57 cases).All patients taking epalrestat,observation groups were given joint administration CSDP on the basis of epalrestat.The clinical efficacy of the two groups of patients after treatment were compared,two groups of patients' perception threshold were measured before and after treatment,as well as EMG motor and sensory nerve conduction velocitywere compared.Results After treatment,the observation group total effective rate(94.74%) was significantly higher(85.97%) than the control group,which the difference was a statistically significant(F <0.05);after treatment,the perception threshold observation group of patients(2.5 ± 0.5) was significantly lower than the control group(3.6 ± 0.7),which the difference was a statistically significant(F <0.05);after treatment,observation group of patients with EMG motor and sensory nerve conduction velocity was significantly faster than the control group,which the difference was a statistically significance(F <0.05).Conclusions CSDP Joint epalrestat treatment of type 2 diabetic peripheral neuropathy,which can be increased in patients' nerve conduction velocity and get a good clinical efficacy,it is widely used.
引文
[1]宋秀霞,姜涛,张敏等.2型糖尿病周围神经病变与代谢综合征相关性探讨[J].天津医药,2012,40(7):655-657.
[2]Alejandro H,Robert D.Pitceathly,C.et al.Peripheral neuropathy?predicts nuclear gene defect in patients with mitochondrial ophthalmoplegia[J].Brain.2014,137(12):3200-3212.
[3]崔黎黎,赵传胜.2型糖尿病患者胰岛素抵抗与合并周围神经病变的相关性分析[J].中国医科大学学报,2012,41(8):734-737.
[4]冯瑞.依帕司他联合甲钴胺治疗2型糖尿病周围神经病变的临床疗效与电生理变化研究[J].中国现代医学杂志,2014,24(36):77-80.
[5]沈娟,曾辉,李连喜等.振动感觉阈值(VFt)在糖尿病周围神经病变(DPN)中的诊断价值[J].复旦学报(医学版),2013,40(1):31-37.
[5]傅明捷,何明坤,王艳等.甲钴胺联合依帕司他治疗老年糖尿病周围神经病变42例[J].中国老年学杂志,2013,33(8):1892-1893.
[7]阮园,马建华,谢晓竞等.依帕司他与甲钴胺联合治疗糖尿病周围神经病变疗效的Meta分析[J].江苏医药,2012,38(3):278-280.
[8]王星娜,朱筱.中药足浴联合甲钴胺治疗糖尿病周围神经病变的疗效观察[J].中国现代医学杂志,2013,23(15):73-75.
[9]Kevin L.Farmer L,Rick T.et al.Dobrowsky.Diabetic?Peripheral Neuropathy Should a Chaperone Accompany Our Therapeutic Approach[J].Pharmacol Rev.2012,64(4):880-900.
[10]贾佳,余江觳.依帕司他治疗糖尿病周围神经病变的Meta分析[J].中国糖尿病杂志,2013,21(9):782-788.
[11]杨丕坚,李舒敏,吕以培等.复方丹参滴丸对早期糖尿病视网膜病变患者血管内皮功能的影响[J].中国实验方剂学杂志,2013,19(8):340-343.
[12]关秀军,邓斌,周旭军等.复方丹参滴丸对2型糖尿病合并冠心病患者血管硬化的影响及心脑血管事件的预防作用[J].时珍国医国药,2013,24(2):490-491.
[13]韩琳娜,李一梅,谢波等.复方丹参滴丸治疗非增生期糖尿病视网膜病变的研究进展[J].中成药,2015,37(2):382-384.
[14]王杨,刘畅.依帕司他治疗糖尿病周围神经病变的疗效及机制[J].中国老年学杂志,2015,14(1):93-95.
[15]赵方宏.依帕司他治疗糖尿病周围神经病变60例[J].中国老年学杂志,2012,32(7):1486-1487.
[2]Alejandro H,Robert D.Pitceathly,C.et al.Peripheral neuropathy?predicts nuclear gene defect in patients with mitochondrial ophthalmoplegia[J].Brain.2014,137(12):3200-3212.
[3]崔黎黎,赵传胜.2型糖尿病患者胰岛素抵抗与合并周围神经病变的相关性分析[J].中国医科大学学报,2012,41(8):734-737.
[4]冯瑞.依帕司他联合甲钴胺治疗2型糖尿病周围神经病变的临床疗效与电生理变化研究[J].中国现代医学杂志,2014,24(36):77-80.
[5]沈娟,曾辉,李连喜等.振动感觉阈值(VFt)在糖尿病周围神经病变(DPN)中的诊断价值[J].复旦学报(医学版),2013,40(1):31-37.
[5]傅明捷,何明坤,王艳等.甲钴胺联合依帕司他治疗老年糖尿病周围神经病变42例[J].中国老年学杂志,2013,33(8):1892-1893.
[7]阮园,马建华,谢晓竞等.依帕司他与甲钴胺联合治疗糖尿病周围神经病变疗效的Meta分析[J].江苏医药,2012,38(3):278-280.
[8]王星娜,朱筱.中药足浴联合甲钴胺治疗糖尿病周围神经病变的疗效观察[J].中国现代医学杂志,2013,23(15):73-75.
[9]Kevin L.Farmer L,Rick T.et al.Dobrowsky.Diabetic?Peripheral Neuropathy Should a Chaperone Accompany Our Therapeutic Approach[J].Pharmacol Rev.2012,64(4):880-900.
[10]贾佳,余江觳.依帕司他治疗糖尿病周围神经病变的Meta分析[J].中国糖尿病杂志,2013,21(9):782-788.
[11]杨丕坚,李舒敏,吕以培等.复方丹参滴丸对早期糖尿病视网膜病变患者血管内皮功能的影响[J].中国实验方剂学杂志,2013,19(8):340-343.
[12]关秀军,邓斌,周旭军等.复方丹参滴丸对2型糖尿病合并冠心病患者血管硬化的影响及心脑血管事件的预防作用[J].时珍国医国药,2013,24(2):490-491.
[13]韩琳娜,李一梅,谢波等.复方丹参滴丸治疗非增生期糖尿病视网膜病变的研究进展[J].中成药,2015,37(2):382-384.
[14]王杨,刘畅.依帕司他治疗糖尿病周围神经病变的疗效及机制[J].中国老年学杂志,2015,14(1):93-95.
[15]赵方宏.依帕司他治疗糖尿病周围神经病变60例[J].中国老年学杂志,2012,32(7):1486-1487.